Pfizer Unveils Key Infectious Disease Data at IDWeek 2026
Event summary
- Pfizer will present data from over 50 abstracts at IDWeek 2026, including 12 oral presentations on infectious disease advancements.
- Key highlights include Phase 2 data for a 25-valent pneumococcal vaccine candidate and Phase 3 results for a Lyme disease vaccine.
- Real-world studies on ABRYSVO's effectiveness against RSV in nursing home residents and infants will be presented.
- The EMA has started reviewing the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate.
The big picture
Pfizer's extensive data presentation at IDWeek 2026 underscores its strategic focus on addressing urgent infectious disease challenges through innovative vaccines and therapies. The company's emphasis on real-world evidence and next-generation vaccine candidates aligns with broader industry trends towards personalized and preventive healthcare solutions. With a portfolio spanning pneumococcal, Lyme disease, RSV, and COVID-19 vaccines, Pfizer is positioning itself as a key player in the global fight against infectious diseases.
What we're watching
- Regulatory Progress
- Whether the EMA's review of the Lyme disease vaccine candidate will lead to expedited approval and market entry.
- Vaccine Efficacy
- How the real-world effectiveness data of ABRYSVO will impact its adoption in high-risk populations.
- Pipeline Advancements
- The pace at which Pfizer's next-generation pediatric pneumococcal vaccine candidate advances through Phase 3 trials.
Related topics
